11/15/2026

Janusmed amning

Janusmed amning – Natalizumab

Janusmed amning tillhandahåller generella rekommendationer om huruvida ett friskt fullgånget spädbarn kan ammas när modern använder olika läkemedel. Observera att prematura och/eller sjuka spädbarn alltid kräver särskilda överväganden. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed amning och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Natalizumab

Natalizumab

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. SPC TYSABRI 300 mg, Biogen Idec Ltd. 10/2013. Citerad 150420

  2. Baker TE, Cooper SD, Kessler L, Hale TW. Transfer of natalizumab into breast milk in a mother with multiple sclerosis. J Hum Lact. 2015;31(2):233-6.

  3. Proschmann U, Thomas K, Thiel S, Hellwig K, Ziemssen T. Natalizumab during pregnancy and lactation. Mult Scler. 2018;24(12):1627-1634.

  4. Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development. Gastroenterology. 2018;155(3):696-704.

  5. Hainke U, Sehr T, Eisele J, Thomas K, Ziemssen T. Natalizumab: Passage into breast milk and neonatal blood. Multiple sclerosis. 2015;23:690. Abstract EPI1324 DOI: 10.1177/1352458515602639.

  6. Ciplea AI, Langer-Gould A, de Vries A, Schaap T, Thiel S, Ringelstein M et al. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e723.

  7. Callegari I, Schneider M, Aebischer V, Voortman MM, Proschmann U, Ziemssen T et al. Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis. Ther Adv Neurol Disord. 2023;16:17562864221150040.

  8. Witt L, Friedmann N, Haben S, Dost-Kovalsky K, Bast N, Oganowski T et al. Safety of breastfeeding under monoclonal antibodies in the offspring of mothers with multiple sclerosis or neuromyelitis optica spectrum disorder. J Neurol Neurosurg Psychiatry. 2026 May;97(6):522-531.

  9. Carrozzo G, Pinardi F, Lugaresi A. Long-term safety evaluation of natalizumab during pregnancy and lactation in patients with multiple sclerosis. Neurol Sci. 2025;46(8):3797-3802.

  10. Camilli F, Carrozzo G, Bandini A, Pinardi F, Lugaresi A. Maternal and neonatal outcomes of natalizumab and anti-CD20 monoclonal antibody exposure during pregnancy and lactation in Multiple Sclerosis. Mult Scler J. 2025;3(31):1363-4.

  1. SPC TYSABRI 300 mg, Biogen Idec Ltd. 10/2013. Citerad 150420
  2. Baker TE, Cooper SD, Kessler L, Hale TW. Transfer of natalizumab into breast milk in a mother with multiple sclerosis. J Hum Lact. 2015;31(2):233-6.
  3. Proschmann U, Thomas K, Thiel S, Hellwig K, Ziemssen T. Natalizumab during pregnancy and lactation. Mult Scler. 2018;24(12):1627-1634.
  4. Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development. Gastroenterology. 2018;155(3):696-704.
  5. Hainke U, Sehr T, Eisele J, Thomas K, Ziemssen T. Natalizumab: Passage into breast milk and neonatal blood. Multiple sclerosis. 2015;23:690. Abstract EPI1324 DOI: 10.1177/1352458515602639.
  6. Ciplea AI, Langer-Gould A, de Vries A, Schaap T, Thiel S, Ringelstein M et al. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e723.
  7. Callegari I, Schneider M, Aebischer V, Voortman MM, Proschmann U, Ziemssen T et al. Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis. Ther Adv Neurol Disord. 2023;16:17562864221150040.
  8. Witt L, Friedmann N, Haben S, Dost-Kovalsky K, Bast N, Oganowski T et al. Safety of breastfeeding under monoclonal antibodies in the offspring of mothers with multiple sclerosis or neuromyelitis optica spectrum disorder. J Neurol Neurosurg Psychiatry. 2026 May;97(6):522-531.
  9. Carrozzo G, Pinardi F, Lugaresi A. Long-term safety evaluation of natalizumab during pregnancy and lactation in patients with multiple sclerosis. Neurol Sci. 2025;46(8):3797-3802.
  10. Camilli F, Carrozzo G, Bandini A, Pinardi F, Lugaresi A. Maternal and neonatal outcomes of natalizumab and anti-CD20 monoclonal antibody exposure during pregnancy and lactation in Multiple Sclerosis. Mult Scler J. 2025;3(31):1363-4.

Innehållet senast uppdaterat 11/3/2026